免疫机制和免疫调节疗法在类固醇耐药性性综合征的免疫机制和免疫调节疗法
Junchao Deng1, Lizhen Zhu2, Xiaoshi Zhu1
1Department of Pediatrics, Sichuan Academy of Medical Sciences and Sichuan People's Hospital, Chengdu, PR China.
Renal failure
|December 11, 2025
概括
类固醇耐药性综合征 (SRNS) 是一种对类固醇耐药的病. 新的精确免疫调节策略提供了向治疗,以阻止其进展.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- 类固醇耐药性综合征 (SRNS) 是一种严重的病,导致慢性功能障碍.
- 它的特点是持续的蛋白尿尽管皮质类固醇治疗.
- 目前的治疗方法有效性有限,需要新的治疗方法.
研究的目的:
- 审查SRNS背后的免疫机制.
- 探索SRNS的新兴精确免疫调节策略.
- 讨论SRNS的个性化和向性疗法.
主要方法:
- 关于SRNS病原和治疗的综合文献综述.
- 专注于免疫细胞网络,细胞因子和细胞损伤.
- 对新型治疗点和个性化医疗方法的分析.
主要成果:
- SRNS涉及复杂的免疫细胞相互作用,促炎性细胞因子和 podocyte 损伤.
- 新兴疗法包括IL-17,IL-12,CD38,C5/B因子,Rho激酶和caspase的调节.
- 使用基因分析和生物标志物的个性化策略正在推进定制干预.
结论:
- 向疗法解决SRNS异质性,并尽量减少免疫抑制.
- 精确免疫调节为停止SRNS进展提供了新的希望.
- 未来的研究应该专注于组合疗法和机械分层,以获得最佳结果.
相关概念视频
Nephrotic Syndrome III : Nursing Management
269
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
269
Nephrotic Syndrome II : Assessment and Medical Management
180
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
180
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
Nephrotic Syndrome I : Introduction
469
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
469
Inflammatory Bowel Disease IV: Pharmacological Management
445
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
445
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
408
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
408


